AfC Special Educational Needs and Disabilities Information Advice and Support Services (SENDIASS)
Open- Buyer
- Achieving for Children
- Location
- Twickenham
- Deadline
- Closes 16 Nov 2026
- Value
- £1.2m
Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.
NHS England has published 466 tender notices since 16 Nov 2023, with a combined advertised value of £120bn. 71 of them are currently open.
Tender documents and submissions are handled on the official portal (Find a Tender). Register there to download the documents and submit your response before the deadline.
View the original notice on Find a TenderUpload the tender documents and mytender.io drafts compliant answers from your own past bids, case studies and policies, so your team spends its time improving the bid rather than starting from a blank page.
Source: Find a Tender. Contains public sector information licensed under the Open Government Licence v3.0. Details may change; always check the original notice before bidding.